Welcome to our dedicated page for Maxcyte news (Ticker: MXCT), a resource for investors and traders seeking the latest updates and insights on Maxcyte stock.
MaxCyte, Inc. (MXCT) pioneers advanced cell engineering through its proprietary Flow Electroporation technology, enabling breakthroughs in gene therapy and biopharmaceutical development. This dedicated news hub provides investors and industry professionals with essential updates on MXCT’s strategic initiatives, financial performance, and scientific advancements.
Access timely press releases covering regulatory milestones, partnership announcements, and technology innovations. Our curated collection includes earnings reports, clinical trial updates, and analyses of MXCT’s role in advancing next-generation cell therapies. The platform serves as a critical resource for tracking the company’s impact on precision medicine and scalable therapeutic manufacturing.
Discover updates about MXCT’s ExPERT platform deployments, licensing agreements with biotech innovators, and expansions in global research collaborations. Content is organized for quick scanning while maintaining technical accuracy, ensuring relevance for both casual observers and specialized analysts.
Bookmark this page for streamlined access to verified MXCT developments. Combine our news feed with Stock Titan’s financial tools to monitor how MaxCyte’s cell engineering leadership translates into long-term market positioning.
MaxCyte, Inc. reported a total revenue of $11.3 million in the first quarter of 2024, marking a 32% increase year-over-year. Core business revenue grew by 5% to $8.2 million. The company signed four Strategic Platform License (SPL) clients year-to-date, with a total of 27 partners. Cash, cash equivalents, and investments stood at $202.5 million as of March 31, 2024. MaxCyte affirmed its 2024 revenue guidance, expecting flat to 5% growth in core business revenue and approximately $5 million in SPL Program-related revenue.
FAQ
What is the current stock price of Maxcyte (MXCT)?
What is the market cap of Maxcyte (MXCT)?
